JCL roundtable: Managing lipid disorders in patients with HIV

Area of Science:

• Infectious Diseases
• Cardiovascular Health
• Metabolic Disorders

Background:

• The human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) epidemic poses significant challenges in infectious disease management.
• Antiretroviral therapies have dramatically improved patient longevity but introduced concerns regarding metabolic syndrome and dyslipidemia, notably elevated triglycerides.
• Drug metabolism interactions between antiviral agents and lipid-lowering therapies complicated early management strategies.

Purpose of the Study:

• To discuss the evolution of managing lipid abnormalities in patients with HIV infection.
• To share insights on controlling metabolic complications arising from antiretroviral drug use.
• To address strategies for reducing vascular disease risk in the context of HIV/AIDS management.

Main Methods:

• A roundtable discussion format was employed.
• Four physicians with extensive experience in managing large cohorts of HIV-infected patients participated.
• Participants focused on their expertise in managing lipid disorders and mitigating vascular disease risk.

Main Results:

• Initial antiretroviral drugs were associated with significant lipid abnormalities, including hypertriglyceridemia.
• Improved understanding and management strategies have enhanced control over these lipid disorders.
• Physician experience has led to better control of metabolic issues and reduced vascular disease risk in HIV patients.

Conclusions:

• Management of lipid abnormalities in HIV-infected patients has evolved significantly.
• Current antiretroviral agents and accumulated clinical experience allow for better control of metabolic complications.
• Effective management strategies can mitigate vascular disease risk in individuals living with HIV/AIDS.